Board of Directors
- Overview
- Stock Information
- News & Events
- SEC Filings
- Analyst Coverage
- Corporate Governance
- Shareholder Services
- Corporate Presentation
Kathy Rouan, Ph.D.
Dr. Rouan has nearly 30 years of pharmaceutical industry experience and most recently served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) at GlaxoSmithKline (GSK). GSK’s PCPS encompasses the company’s global clinical operations, statistics and programming, clinical pharmacology, GCP quality, third party resourcing and project management functions and includes approximately 1,800 individuals in 20 countries. Dr. Rouan first joined GSK in 1989 with a background in pharmaceutical sciences, focusing on formulation development of protein pharmaceuticals. In 1993, she transitioned into project leadership and management becoming vice president and head of metabolism and pulmonary project management in 1999. In 2007, Dr. Rouan led the development, submission and approval of Arzerra® (ofatumumab) for refractory chronic lymphocytic leukemia. In 2012, she became head of biopharmaceutical development, assuming responsibility for delivery of GSK’s portfolio of biopharmaceutical medicines. In December 2013, Dr. Rouan was appointed senior vice president and head of research and development for Stiefel, GSK’s dermatology therapy area unit. Dr. Rouan earned a Ph.D. in pharmaceutical sciences from the University of Rhode Island and a B.Pharm. from the University of London.
